-
Allotment of series J shares
Read More
December 22, 2022 -
Determination of the final issue price of series J shares and the final number of series J shares that will be offered in the public offering
Read More
December 15, 2022 -
Ryvu Therapeutics presents Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting
Read More
December 11, 2022 -
Approval of the prospectus of the Company
Read More
December 7, 2022 -
Decision to conduct public offering of J series shares in December 2022
Read More
December 2, 2022 -
Disclosure of delayed confidential information regarding the start of negotiations and the non-binding determination of the key terms of a potential collaboration
Read More
November 30, 2022 -
Execution of an exclusive Research Collaboration Option and Exclusive License Agreement and Equity Investment Agreement with BioNTech SE
Read More
November 30, 2022 -
Clinical and Translational Data of RVU120 and SEL24 (MEN1703) to be presented at the 2022 American Society of Hematology (ASH) Annual Meeting
Read More
November 3, 2022 -
Ryvu Therapeutics presents new clinical and preclinical data for RVU120 program at 34th AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
Read More
October 26, 2022 -
Posters to be presented at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
Read More
October 12, 2022 -
Adoption by the Company’s Management Board of a resolution on issuance of shares within the framework of authorized capital and conclusion of lock-up agreements
Read More
October 5, 2022 -
Registration of an amendment to the Company’s Articles of Association
Read More
October 3, 2022 -
Shareholders controlling at least 5% of the votes at the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A. convened on September 19th, 2022
Read More
September 19, 2022 -
Resolutions adopted by the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
September 19, 2022 -
Self-correction to the draft resolution of the General Meeting of Ryvu Therapeutics S.A. convened for September 19, 2022
Read More
September 14, 2022 -
Convening of the Extraordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
August 19, 2022 -
Ryvu Therapeutics’ development plans for 2022-2024
Read More
August 19, 2022 -
Change of the date of publication of the periodic report for the first half of 2022
Read More
August 18, 2022 -
Conclusion of a financing agreement with the European Investment Bank
Read More
August 17, 2022 -
Changes in Ryvu’s Management Board
Read More
July 26, 2022
Report: Current Stock Reports
Title